PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91-106.Dey, N.; De, P.; Leyland-Jones, B. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor
这表明肿瘤细胞中CDK4/6底物的表达/激活状态，以及肿瘤上皮细胞及其周围基质/免疫细胞中独立于基因组的PI3K/AKT/mTOR信号通路的激活，可能预测HR+/HER2-晚期乳腺癌患者对CDK4/6抑制剂联合ET的反应，有助于为这类患者制定更为个性化的治疗方案。参考文献：[1]NCCN Guidelines Breast Cancer Version 3. 2024. June ...
PI3K/Akt/mTOR inhibitors in breast cancer PI3K / Akt / mTOR抑制剂在乳腺癌中的作用 ★ 1.Abstract 概述 ◆ Activation of the phosphoinositide【磷酸肌醇】 3 kinase (PI3K)/Akt/mammalian 【 [mæˈmeɪliən] 】...
Among these inhibitors, capivasertib and alpelisib have received approval as targeted therapies for this indication. This review provides a comprehensive summary of the latest developments in PI3K/AKT/mTOR inhibitors for HR+ breast cancer. It also delves into different aspects, including sampling, ...
这表明肿瘤细胞中CDK4/6底物的表达/激活状态,以及肿瘤上皮细胞及其周围基质/免疫细胞中独立于基因组的PI3K/AKT/mTOR信号通路的激活,可能预测HR+/HER2-晚期乳腺癌患者对CDK4/6抑制剂联合ET的反应,有助于为这类患者制定更为个性化的...
2024年11月,Cancer Treatment Reviews在线发表了一篇名为“PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer”的综述,总结了PI3K/AKT/mTOR抑制剂在HR+晚期乳腺癌的最新进展,并进一步讨论了这些抑制剂在临床实践中使用的诊断测试和其他考虑因素[6]。本文整理PI3K/AKT/mTOR抑制剂的作用机制...
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. hTere is preclinical data to support inhibition of the pathway, and phase I to III trials involving inhibitors of the pathway have been or are being conducted in soli...
MicroRNA expression in breast cancer (BC) is explored both as a potential biomarker and for therapeutic purposes. Recent studies have revealed that miR-203a-3p is involved in BC, and importantly contributes to BC chemotherapy responses; however, the regu
这篇综述聚焦肝细胞癌(HCC),深入剖析 PI3K/AKT/mTOR 通路在其发病机制中的关键作用,梳理相关临床试验进展,探讨抑制剂治疗的利弊,并提出联合治疗及纳米技术应用等潜在方向,为 HCC 治疗研究提供全面参考。 1. 引言 肝细胞癌(HCC)是最常见的原发性肝癌,全球每年近 90 万人患病,超 83 万人死亡,亚洲发病率最高。其...
Western blot 显示(XIi)显著抑制 PI3K/AKT/mTOR 通路,尤其在雌激素存在时,或与他莫昔芬在雌激素受体阳性乳腺癌中存在协同作用。PI3K 激酶抑制实验表明(XIi)呈剂量依赖性抑制 PI3K-α,高浓度时与 PI-103 相当。对接研究显示(XIi)与 PI3Kα 亚型结合亲和力强。综上,穿心莲内酯衍生物,尤其是(XIi),有望成为对抗...